P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY
Ellen Ritchie,
Tara L. Lin,
Laura F. Newell,
Robert K. Stuart,
Scott Solomon,
Richard Stone,
Gary Schiller,
Matthew Wieduwilt,
Eileen Amy Ryan,
Nalina Dronamraju,
Jeffrey Lancet,
Jorge Cortes
Affiliations
Ellen Ritchie
1 Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, United States
Tara L. Lin
2 University of Kansas Medical Center, Kansas City, KS, United States
Laura F. Newell
3 Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, United States
Robert K. Stuart
4 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States
Scott Solomon
5 Northside Hospital Cancer Institute, Atlanta, GA, United States
Richard Stone
6 Dana-Farber Cancer Institute, Boston, MA, United States
Gary Schiller
7 David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
Matthew Wieduwilt
8 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States
Eileen Amy Ryan
9 University of Rochester, Rochester, New York, NY, United States
Nalina Dronamraju
10 Jazz Pharmaceuticals, Philadelphia, PA, United States
Jeffrey Lancet
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
Jorge Cortes
12 Georgia Cancer Center, Augusta University, Augusta, GA, United States
